Probiodrug to
Present Data from its Phase 2a SAPHIR Study at International
Alzheimer's Disease Conference
Prof. Philipp
Scheltens, Principal Investigator of the study, to present at
Clinical Trials on Alzheimer's Disease (CTAD) 2017 in
Boston
Management will
host a conference call with Dr. Scheltens to discuss the data on 2
November 2017 at 11:00am ET / 16:00pm CET
HALLE (SAALE),
Germany, 25 October 2017 - Probiodrug AG (Euronext
Amsterdam: PBD), a biopharmaceutical company developing novel
therapeutic solutions to treat Alzheimer's disease (AD), today
announced that it will present the data of the Phase 2a SAPHIR
Study at CTAD 2017 in Boston, MA, USA.
Prof. Philip Scheltens, MD, PhD,
Principal Investigator of the study, will present during the Late
Breaking Oral Communications session on Wednesday, 1 November 2017,
at 5:45pm EDT in General Ballroom AB of the Boston Park Plaza
Hotel. The presentation is entitled "Phase 2a
study results with the glutaminylcyclase inhibitor PQ912 in early
Alzheimer's Disease".
Probiodrug reported topline data of the SAPHIR
trial in June (Probiodrug announces encouraging results of the
Phase 2a SAPHIR Study)
Based on the rich set of information from the
SAPHIR study, Probiodrug has started tailoring a core Phase2b
program focusing on optimal-dose finding and longer treatment
duration in the early AD patient population. In parallel,
partnering discussions will continue (Probiodrug initiates Phase 2b
core program of PQ912 and details further strategy).
Webcast and Conference
Call
Probiodrug will host a webcast and
conference call at which Prof. Philip Scheltens will share the data
set and answer questions on Thursday, 2 November 2017 at 11:00am ET
(16:00pm CET). To participate in the conference call, please call
one of the following numbers ten minutes prior to commencement:
Toll-Free
Germany: 0 800 182 0040
Toll-Free US & Canada: +1
877-407-6951
International: +1
412-902-0046
To register for the webcast, please visit the
Events page at www.probiodrug.de or click here.
###
For more
information, please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume
Brophy
Conor Griffin, Alexander Protsenko, Jonothan Blackbourn
Tel: +44 (0) 20 7862 6381
Email: probiodrug@humebrophy.com
The Trout
Group
Tricia Truehart, Kelly Mueller
Tel: +1 (646) 378-2953
Email: ttruehart@troutgroup.com
MC Services AG
Anne Hennecke, Caroline Bergmann
Tel: +49 (0) 211 529 252 20
Email: probiodrug@mc-services.eu
Notes to
Editors:
About Probiodrug AG
Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical
company focused on the development of new therapeutic products for
the treatment of Alzheimer's disease (AD). Probiodrug has
identified a new therapeutic concept linked to Alzheimer's disease
initiation and progression. The development approaches are
targeting a key neuro/synaptotoxic component of the pathology,
pyroglutamate-Abeta (pGlu-Abeta, N3pG) as a therapeutic
strategy.
Probiodrug's lead product
candidate, PQ912, is a highly specific and potent inhibitor of
Glutaminyl Cyclase (QC), which has shown therapeutic effects in AD
animal models. A Phase 1 study with healthy young and elderly
volunteers revealed a dose dependent exposure and showed good
safety and tolerability up to the highest dose showing >90%
target occupancy in the spinal fluid. In June 2017 Probiodrug
announced top-line data of the Phase 2a SAPHIR trial of its lead
candidate (Probiodrug announces encouraging results of the Phase 2a
SAPHIR Study ). The positive effects seen on secondary exploratory
efficacy markers are strongly supporting (a) the hypothesis of
pGlu-Abeta being synaptotoxic and (b) the therapeutic concept
pursued by Probiodrug. The study revealed a positive benefit risk
ratio of PQ912 and provides important guidance how to move forward
in the development of PQ912 as a disease-modifying drug for AD.
Altogether, the results make the program highly attractive for
further development.
Complementary to the small
molecule PQ912 inhibiting the formation of the synaptotoxic agent
pGlu-Abeta, the company is developing PBD-C06, an
anti-pGlu-Abeta-specific monoclonal antibody.The Company has
medical use and composition of matter patents related to the
inhibition of QC and anti-pGlu-Abeta-specific monoclonal
antibodies, and has, in the Company's view, a leading position in
this field of research.
Founded in 1997 by Hans-Ulrich
Demuth and Konrad Glund, the company successfully developed a novel
therapeutic concept for diabetes - the DP4 inhibitors - which
provided the basis for a novel class of antidiabetics - the
gliptins. Its core capabilities are based on its long-standing
expertise in the elucidation of the structure and function of
enzymes involved in the modification of proteins and peptides,
which play a central role in pathological conditions.
Today, Probiodrug aims to become a
leading company in the development of AD treatments and to thereby
provide a better life for Alzheimer's disease patients.
www.probiodrug.de
About Alzheimer's
disease
Alzheimer's disease is a neurological disorder, which is the most
common form of dementia, and ultimately leads to death. Because
Alzheimer's disease cannot be cured and is degenerative, the
affected patients must increasingly rely on others for assistance.
Today, 47 million people live with dementia worldwide, and this
number is projected to treble to more than 131 million by 2050, as
populations age. Dementia also has a huge economic impact.
Alzheimer's has an estimated, global societal cost of US$ 818
billion, and it will become a trillion dollar disease by 2018.
(World Alzheimer Report 2016).
Forward Looking
Statements
Information set forth in this press release
contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of Probiodrug AG as of the date of
this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.